School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Indivior Pharmaceuticals, Inc. INDV

Healthcare · Drug Manufacturers - Specialty & Generic

$35.42last close 2026-10-13 · market cap $4.18B · delayed data

Trailing returns

1M+2.70%
3M-11.91%
6M+12.09%
1Y+48.39%
5Y+129.26%

Basis: Adjusted daily closes.

What it does

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.

Open INDV in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies